Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Hum Pathol ; 45(2): 249-58, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24289969

RESUMO

The use of digital imaging techniques for biomarker assessment has gained recognition as a valid tool for clinical use. In this study, we used image analysis for evaluation of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER2), Ki-67 index, and p53 in 172 patients with invasive breast cancer treated with neoadjuvant chemotherapy and compared it with an untreated group (100 cases). We also examined the relationship between biomarker expression and the extent of residual disease using the Web-based MD Anderson residual cancer burden (RCB) calculator. Residual disease was classified as RCB 0/I, II, and III corresponding to complete/near-complete response, moderate, and extensive residual disease, respectively. Overall change in ER, PR, and HER2 status in the treated group was seen in 9.02% (P = .0148), 18.4% (P = .011), and 12.0% (P = .0042), respectively. Change in HER2 status, positive to negative and negative to positive, occurred in 27.2% and 7.0%, respectively. The group with RCB 0/I was frequently younger (P = .0057) and showed higher ER(-) status (P = .0316), lower ER scores (P = .0103), higher Ki-67 index (P = .0008), and p53 (P = .0055) compared with those with RCB II and III. Pathologic tumor stage (P = .0072), lumpectomy versus mastectomy (P = .0048), and p53 expression (P = .0190) were independent predictors of recurrence-free survival. The RCB categories (P = .0003) and tumor grade (P = .0049) were independent predictors of overall survival. This is the first study to conduct a comprehensive analysis of biomarkers in neoadjuvant chemotherapy-treated patients versus an untreated group using the digital image analysis method. We have demonstrated for the first time the relationship between RCB, tumor biomarkers expression, and clinical outcome.


Assuntos
Biomarcadores Tumorais/biossíntese , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Neoplasia Residual/metabolismo , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/mortalidade , Neoplasias da Mama/terapia , Feminino , Humanos , Interpretação de Imagem Assistida por Computador , Estimativa de Kaplan-Meier , Antígeno Ki-67/biossíntese , Pessoa de Meia-Idade , Terapia Neoadjuvante , Neoplasia Residual/patologia , Prognóstico , Receptor ErbB-2/biossíntese , Receptores de Estrogênio/biossíntese , Receptores de Progesterona/biossíntese , Estudos Retrospectivos , Carga Tumoral , Proteína Supressora de Tumor p53/biossíntese
2.
J Biopharm Stat ; 21(3): 393-404, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21442515

RESUMO

We consider Bayesian point and interval estimation for a risk ratio of two proportion parameters using two independent samples of binary data subject to misclassification. In order to obtain model identifiability, we apply a double sampling scheme. For the identifiable model, we propose a Bayesian method for statistical inference for a two proportion risk ratio. Specifically, we derive an easy-to-implement closed-form sampling algorithm to draw from the posterior distribution of interest. We demonstrate the efficiency of our algorithm for Bayesian inference via Monte Carlo simulation studies and using a real data example.


Assuntos
Algoritmos , Teorema de Bayes , Simulação por Computador , Modelos Estatísticos , Método de Monte Carlo , Humanos , Razão de Chances , Projetos de Pesquisa , Processos Estocásticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA